Q-Line Biotech NSE SME IPO review

  • The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
  • It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
  • As the company has no listed peers, it is trying to extract fancy price for its IPO.
  • Based on its overall financial data, the issue appears fully priced.
  • Well-informed investors may park moderate funds for long term.
Dilip Davda

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges. 

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies. 

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Q-Line Biotech IPO

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share.  The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes. 

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr. 

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained. 

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended Revenue Expense PAT Assets
2023 ₹184.81 ₹154.97 ₹32.10 ₹251.58
2024 ₹206.45 ₹175.85 ₹34.44 ₹339.25
2025 ₹322.58 ₹261.43 ₹28.13 ₹455.49
Dec 2025 ₹236.50 ₹186.96 ₹38.69 ₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects. 

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company Face Value (₹) EPS basic (₹)Ā  EPS Diluted (₹) RONW (%) P/E Ratio NAV (₹)
Powerica Limited 5 15.26Ā  15.26 15.37 %Ā  24.45 99.76
Listed Peers
Cummins India Limited 2 72.15Ā  72.15 26.45% 64.13Ā  272.78
Kirloskar Oil Engines Limited 2 33.71 33.60 15.85% 43.24 212.60
NTPC Green Energy Limited 10 0.67 0.67 2.58% 129.40 21.88
Acme Solar Holdings Limited 2 4.55 4.53 5.59% 50.74Ā  74.54
Adani Green Energy Limited 10 8.37 8.37 11.90%Ā  101.53Ā  76.62
Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion
Q-Line Biotech IPO FAQs
1. What is Q-Line Biotech IPO? āŒ„
Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.
2. When Q-Line Biotech IPO will open for subscription? āŒ„
The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.
3. What is Q-Line Biotech IPO Investors Portion? āŒ„
The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.
4. How to Apply the Q-Line Biotech IPO? āŒ„
You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
5. What is Q-Line Biotech IPO Issue Size? āŒ„
Q-Line Biotech IPO issue size is ₹214 crores.
6. What is Q-Line Biotech IPO Price Band? āŒ„
Q-Line Biotech IPO Price Band is ₹326 to ₹343.
7. What is Q-Line Biotech IPO Lot Size? āŒ„
The minimum bid is 800 Shares with ₹2,74,400 amount.
8. What is the Q-Line Biotech IPO Allotment Date? āŒ„
Q-Line Biotech IPO allotment date is May 26,2026.
9. What is the Q-Line Biotech IPO Listing Date? āŒ„
Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Mukka Proteins IPO Date, Review, Price, Allotment Details

Mukka Proteins IPO Details: Mukka Proteins IPO date is fixed, the IPO is to hit the market on February 29 and will close on March 4. Mukka Proteins IPO to raise around ₹225 crores via IPO that comprises fresh issue of ₹225 crores and offer for sale up to 80,000,000 equity shares ₹1 each. The retail quota is 35%, QIB is 50%, and HNI is 15%.
Mukka Proteins IPO

Consistently being awarded by MPEDA, during the last 7 years for their export performance, inter alia, including outstanding performance in the export of fish meal, fish oil, and allied products for Fiscal 2021, Fiscal 2020, and Fiscal 2019, Mukka Proteins believe that they are one of the key players of the Fish Protein industry in India. In Fiscal 2022, of the total estimated revenue of the Indian fish meal and fish oil industry of ₹13,000 to ₹17,000 million, the revenue of the Company was ₹6,928.87 million thus, being a 45%- 50% contributor to the estimated revenue of the Indian fish meal and fish oil industry for the corresponding period. The Company is also amongst the first few Indian companies to have commercialized insect meal and insect oil (collectively ā€œInsect Proteinā€) as an ingredient for aqua feed, animal feed, and pet food. Fish Protein and Insect Protein are hereinafter, collectively, referred to as ā€œAnimal Proteinā€.


As a manufacturer of Fish Protein products, Mukka Proteins manufactures and supplies fish meal, fish oil, and fish soluble paste which is an essential ingredient in the manufacturing of aqua feed (for fish and shrimp), poultry feed (for broiler and layer) and pet food (dog and cat food). Further, fish oil also finds its application in pharmaceutical products (additionally, Omega-3 pills and related products derived from fish oil are gaining importance as high nutrient and healthy dietary supplements), soap manufacturing, leather tanneries & paint industries. They sell their products domestically and also export them to over 10 countries, including Bahrain, Bangladesh, Chile, Indonesia, Malaysia, Myanmar, Philippines, China, Saudi Arabia, South Korea, Oman, Taiwan and Vietnam.

The Company was originally formed as a partnership firm constituted under the Indian Partnership Act, 1932 under the name ā€œMukka Sea Foods Industriesā€ under a deed of partnership dated March 13, 2003. ā€œMukka Sea Foods Industriesā€ was thereafter converted from a partnership firm to a private limited company under Part IX of the Companies Act, 1956, as ā€œMukka Sea Food Industries Private Limitedā€. For further details, see ā€œHistory and Certain Corporate Mattersā€ on page 247 of this Draft Red Herring Prospectus.


Objects of the Issue

  • Funding working capital requirements of the Company.
  • Investment in the Associate, viz. Ento Proteins Private Limited, for funding its working capital requirements.
  • General Corporate Purposes.

Mukka Proteins IPO Review (Apply or Not)

  • Apply

Brokerage Firm IPO Review

  • Capital Market: To be updated soon
  • Religare Broking: To be updated soon
  • Hem Securities: To be updated soon
  • Arihant Capital: To be updated soon

Mukka Proteins IPO Date & Price Band Details

IPO Open:February 29, 2024
IPO Close:March 4, 2024
IPO Size:Approx ₹224 Crores
Fresh Issue:Approx ā‚¹224 Crores
Offer for Sale:Approx NIL
Face Value:₹1 Per Equity Share
IPO Price Band:₹26 to ₹28 Per Share
IPO Listing on:BSE & NSE
Retail Quota:35%
QIB Quota:50%
 NII Quota:15%
DRHP Draft Prospectus:Click Here
RHP Draft Prospectus:Click Here
Anchor Investors List:Click Here

Mukka Proteins IPO Market Lot

The Mukka Proteins IPO minimum market lot is 535 shares with ₹14,980 application amount. The retail investors can apply up-to 13 lots with 6955 shares or ₹194,740 amount.

ApplicationLot SizeSharesAmount
Retail Minimum1535₹14,980
Retail Maximum136,955₹194,740
S-HNI Minimum147,490₹209,720
B-HNI Minimum6735,845₹1,003,660

Mukka Proteins IPO Allotment & Listing Dates

The Mukka Proteins IPO date is February 29 and the close date is March 4. The Mukka Proteins IPO allotment will be finalized on March 5 and the IPO listing on March 9.

Anchor Investors Allotment:February 28, 2024
IPO Open Date:February 29, 2024
IPO Close Date:March 4, 2024
Basis of Allotment:March 5, 2024
Refunds:March 6, 2024
Credit to Demat Account:March 6, 2024
IPO Listing Date:March 7, 2024

You can check IPO subscription status and IPO allotment status on their respective pages.

Mukka Proteins IPO Form

How to apply for the Mukka Proteins IPO? You can apply for Mukka Proteins IPO via ASBA available in your bank account. Just go to the online bank login and apply via your bank account by selecting the Mukka Proteins IPO in the Invest section. The other option is you can apply for Mukka Proteins IPO via IPO forms downloaded via NSE and BSE. Check out the Mukka Proteins forms – Click BSE Forms & NSE Forms blank IPO forms download, fill, and submit in your bank or with your broker.


Mukka Proteins Company Financial Report

  ₹ in Crores
YearRevenueExpensePAT
2021₹609.95₹598.31₹11.01
2022₹776.15₹741.18₹25.82
2023₹1183.80₹1119.32₹47.52
2023 6M₹612.88₹569.89₹32.98

Mukka Proteins IPO Valuation – FY2023

Check Mukka Proteins IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

Earning Per Share (EPS):₹2.00 per Equity Share
Price/Earning P/E Ratio:N/A
Return on Net Worth (RoNW):34.19%
Net Asset Value (NAV):₹5.86 per Equity Share

Peer Group

  • Avanti Feeds Limited
  • Godrej Agrovet Limited
  • Zeal Aqua Limited
  • Waterbase Limited

Company Promoters

  • Kalandan Mohammed Haris
  • Kalandan Mohammad Arif
  • Kalandan Mohammed Althaf

Mukka Proteins IPO Registrar

Cameo Corporate Services Limited
Phone: +91-44-28460390
Email: priya@cameoindia.com
Website: https://ipo.cameoindia.com/

Mukka Proteins IPO Allotment Status Check

Check Mukka Proteins IPO allotment status on Cameo Corporate website allotment URL. Click Here

Mukka Proteins IPO Lead Managers aka Merchant Bankers

  • Fedex Securities Pvt Ltd

Company Address

Mukka Proteins Limited
Mukka Corporate House,
Door, No. 18-2-16/4, First Cross, NG Road, Attavar
Dakshina, Kannada, Mangaluru – 575 001
Phone: +918244252889
Email: cs@mukkaproteins.com
Website: https://www.mukkaproteins.com/

Mukka Proteins IPO FAQs

What is Mukka Proteins IPO?

Mukka Proteins IPO is a main-board IPO. They are going to raise ₹224 Crores via IPO. The issue is priced at ₹26 to ₹28 pr equity share. The IPO is to be listed on BSE & NSE.

When Mukka Proteins IPO will open?

The IPO is to open on February 29, 2024 for QIB, NII, and Retail Investors.

What is Mukka Proteins IPO Investors Portion?

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

How to Apply the Mukka Proteins IPO?

You can apply for Mukka Proteins IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

How to Apply the Mukka Proteins IPO through Zerodha?

Log in to Console in Zerodha Website or in Application. Go to Portfolio and Click on IPO. You will see the IPO Name “Mukka Proteins”. Click on Bid Button. Enter your UPI ID, Quantity, and Price. Submit IPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Zerodha.

How to Apply the Mukka Proteins IPO through Upstox?

Log in to the Upstox Application with your credentials. Select the IPO. You will see the IPO Name “Mukka Proteins”. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Upstox.

How to Apply the Mukka Proteins IPO through Paytm Money?

Log in to Paytm Money Application with your credentials. Select the IPO. You will see the IPO Name “Mukka Proteins”. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Paytm Money.

What is Mukka Proteins IPO Size?

Mukka Proteins IPO size is ₹224 crores.

What is Mukka Proteins IPO Price Band?

Mukka Proteins IPO Price Band is ā‚¹26 to ₹28.

What is the Mukka Proteins IPO Allotment Date?

Mukka Proteins IPO allotment date is March 5, 2024.

What is the Mukka Proteins IPO Listing Date?

Mukka Proteins IPO listing date is March 7, 2024. The IPO is to list on BSE and NSE.

Note: The Mukka Proteins IPO price band and date are officially announced. The IPO grey market premium (Mukka Proteins IPO Premium) will be added to the IPO grey market page as it will start).

Table of Contents

Picture of Jagat Joshi

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.
Picture of Jagat Joshi

Jagat Joshi

6 Responses

  1. Sir /mam my demat I’d no. Is 1201092600545163. No allotment received but Till date my amount not unblock by yourself. Kindly inform to my bank to unblock amount. Thanks. Awaiting your early reply.

  2. Mukkaprotein ipo not alloted but amount is till block
    Pls guide where to query raised unblocked amount

  3. dear sir there is no allotment to me but my lien still created in my bank account. what should I do for that